Diagnamed Holdings Corp. (CSE: DMED)

Diagnamed Holdings Income Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Cost of Revenue	-	-	0.02	0.02
Gross Profit	-	-	-0.02	-0.02
Selling, General & Admin	0.4	0.65	0.41	0.47
Research & Development	0.38	0.51	0.56	0.2
Operating Expenses	0.78	1.18	1.11	0.67
Operating Income	-0.78	-1.18	-1.14	-0.68
Interest & Investment Income	0.01	0.01	-	-
Currency Exchange Gain (Loss)	0.01	0.02	0	-
Other Non Operating Income (Expenses)	-0.05	-0.08	-	-
EBT Excluding Unusual Items	-0.81	-1.23	-1.13	-0.68
Other Unusual Items	0.2	-0.05	-	-1.26
Pretax Income	-0.61	-1.28	-1.13	-1.95
Net Income	-0.61	-1.28	-1.13	-1.95
Net Income to Common	-0.61	-1.28	-1.13	-1.95
Shares Outstanding (Basic)	80	78	76	56
Shares Outstanding (Diluted)	80	78	76	56
Shares Change (YoY)	0.01%	2.81%	36.38%	-
EPS (Basic)	-0.01	-0.02	-0.01	-0.03
EPS (Diluted)	-0.01	-0.02	-0.01	-0.03
Free Cash Flow	-0.65	-1.07	-0.79	-0.57
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01
EBIT	-0.78	-1.18	-1.14	-0.68

Source: S&P Capital IQ. Standard template. Financial Sources.